SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma

  title={SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma},
  author={J. Hadoux and J. Favier and Jean-Yves Scoazec and Sophie Leboulleux and A. Al Ghuzlan and Caroline Caramella and D. D{\'e}andreis and I. Borget and C{\'e}line Loriot and C. Chougnet and E. Letouz{\'e} and J. Young and L. Amar and J. Bertherat and R. Lib{\'e} and F. Dumont and F. Deschamps and M. Schlumberger and A. P. Gimenez-Roqueplo and E. Baudin},
  journal={International Journal of Cancer},
  • J. Hadoux, J. Favier, +17 authors E. Baudin
  • Published 2014
  • Biology, Medicine
  • International Journal of Cancer
  • Cyclophosphamide–dacarbazine–vincristine regimen is recommended for the treatment of malignant pheochromocytoma and paraganglioma (MPP); however, dacarbazine is the only recognized active drug in neuroendocrine tumours. We investigated the therapeutic benefit of temozolomide (TMZ), an oral alternative to dacarbazine, in patients with MPP. This is a retrospective study of consecutive patients with documented progressive MPP. We examined the correlation between Succinate dehydrogenase B (SDHB… CONTINUE READING
    91 Citations
    Interferon-alpha Treatment for Disease Control in Metastatic Pheochromocytoma/Paraganglioma Patients
    • 9
    SDHB mutation carriers with malignant pheochromocytoma respond better to CVD.
    • 15
    • PDF


    High efficacy and continued tumor shrinkage with cyclophosphamide, vincristine, and dacarbazine (CVD) in patients (Pts) with malignant pheochromocytoma/paraganglioma harboring succinate dehydrogenase subunit B (SDHB) mutations.
    • 3
    • Highly Influential
    Succinate dehydrogenase B gene mutations predict survival in patients with malignant pheochromocytomas or paragangliomas.
    • 307
    • PDF
    O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors
    • 309
    • Highly Influential
    • PDF
    One-year progression-free survival of therapy-naive patients with malignant pheochromocytoma and paraganglioma.
    • 73
    • PDF
    Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
    • M. Kulke, K. Stuart, +6 authors C. Fuchs
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2006
    • 453
    Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
    • 1,121
    A SDHB malignant paraganglioma with dramatic response to temozolomide-capecitabine.
    • 11
    • PDF